Stockscreener 앱 받기
16.86
0.06%
0.010
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
ETFs Investing in Theravance Biopharma Inc Stocks - TradingView
Theravance Biopharma Inc (TBPH) Cash Flow - TradingKey
TBPH|Theravance Biopharma Inc|Price:16.865|Chg%:+0.005 - TradingKey
Theravance Biopharma Inc (TBPH) Balance Sheet - TradingKey
Theravance Biopharma Inc (TBPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Theravance Biopharma Inc (TBPH) Institutional Confidence - TradingKey
Theravance Biopharma Inc (TBPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Theravance Biopharma Inc Revenue Breakdown – FWB:0TB - TradingView
Theravance Biopharma Inc Revenue Breakdown – LS:A1137V - TradingView
Theravance Biopharma Inc (TBPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Theravance Biopharma Inc (TBPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Liquidity Mapping Around (TBPH) Price Events - Stock Traders Daily
Zymeworks Won’t Host Q2 Call Amid Proposed Theravance Deal - Stock Titan
Zymeworks to report Q2 2026 results on August 6, no earnings call due to Theravance Biopharma acquisition plans - Pluang
Theravance Biopharma (TBPH) Hovers Near Support Amidst Quiet Trading SessionProtective Put - dars.gov.et
Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders? - Finansavisen
Theravance stock down 3% after Zymeworks announces buyout - MSN
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders - AOL.com
Theravance Biopharma Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co. - Moomoo
H.C. Wainwright Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Raises Target Price to $17 - Moomoo
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI
TBPHTheravance Biopharma Inc Options - Finviz
If You Invested $1,000 in Theravance Bioph (TBPH) - Stock Titan
Arthur Cox advises on pharmaceutical sector acquisition - ICLG
Theravance Biopharma Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseEarnings Season Review - dars.gov.et
TBPH News | THERAVANCE BIOPHARMA INC (NASDAQ:TBPH) - ChartMill
Zymeworks to pay $17/share for Theravance Biopharma in $929M deal - MSN
Theravance Biopharma Insider Sold Shares Worth $5,791,555, According to a Recent SEC Filing - marketscreener.com
Theravance Biopharma(TBPH.US) 10% Shareholder Sells US$5.79 Million in Common Stock - Moomoo
Funds tied to Eli Samaha trim Theravance Biopharma (TBPH) stake in open-market sales - Stock Titan
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
TBPH SEC FilingsTheravance Bioph 10-K, 10-Q, 8-K Forms - Stock Titan
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP
Zymeworks to Acquire Theravance Biopharma in $929 Million Transaction - Global Legal Chronicle
Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo
Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology
TBPH Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet
Zymeworks to Acquire Theravance Biopharma, Inc. - Indovizka.com
Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus
Zymeworks offers US$929-million for COPD drug maker Theravance - The Globe and Mail
Zymeworks to buy Theravance Biopharma in $929M deal – a look at what this deal means for TBPH shareholders - MSN
Zymeworks Buys Theravance To Execute On New Business Strategy - insights.citeline.com
Theravance Biopharma (TBPH) Downgraded to Hold Following $929M A - GuruFocus
Theravance downgraded at Jones on Zymeworks acquisition - MSN
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareh - GuruFocus
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? - Finviz
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH) - PR Newswire
TBPH Downgraded by Jones TradingRating Changed to Hold - GuruFocus
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Ther - GuruFocus
Theravance, after clinical setbacks, agrees to $929M buyout - BioPharma Dive
Zymeworks bolsters royalty stream with Theravance buy - BioWorld News
Zymeworks expands beyond cancer with $929 million Theravance acquisition - WTVB
Fair Price or Fast Exit? Scrutiny Mounts Over Theravance Biopharma Sale - BriefGlance
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal By Investing.com - Investing.com South Africa
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma - Pharmaceutical Executive
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal - Investing.com
Zymeworks to Acquire Theravance for $929 Million, But Discounted Price Triggers Shareholder Investigation - finance.biggo.com
2.44%
0.02%
자본화:
|
볼륨(24시간):